Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other

JAMA Oncol. 2019 Jan 1;5(1):17-18. doi: 10.1001/jamaoncol.2018.4039.

Authors

Jennifer A Flemming^{1

2}, Norah A Terrault^{3

4}

Affiliations

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
³ Department of Medicine, University of California, San Francisco.
⁴ Department of Transplant Surgery, University of California, San Francisco.

PMID: 30267036
DOI: 10.1001/jamaoncol.2018.4039

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antiviral Agents*
Carcinoma, Hepatocellular*
Cohort Studies
Guanine / analogs & derivatives
Hepatitis B, Chronic*
Humans
Liver Neoplasms*
Republic of Korea
Tenofovir

Substances

Antiviral Agents
entecavir
Guanine
Tenofovir